Publications by authors named "Hypatia Hou"

Article Synopsis
  • Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver condition with limited treatment options and relies on manual biopsies for assessment, which often shows high variability among readers.
  • A new artificial intelligence (AI) system, AIM-MASH, has been developed and validated across multiple sites to assist pathologists in scoring liver biopsies related to MASH, showing high reliability and consistency compared to traditional methods.
  • AIM-MASH significantly improved the accuracy of assessing key factors like inflammation and MASH resolution when used by expert pathologists, suggesting it can reduce variability and enhance the evaluation of new treatments in MASH clinical trials.
View Article and Find Full Text PDF
Article Synopsis
  • - The standard method for assessing metabolic dysfunction-associated steatosis in clinical trials is by evaluating liver biopsies on glass slides; however, shipping these slides poses logistical challenges and risks of damage.
  • - This study found that using digital images on the AISight whole slide image management system for assessing steatohepatitis offers comparable accuracy to traditional glass slide evaluations, with both methods verified against a consensus score from expert pathologists.
  • - The results showed that the agreement between digital scoring and the established "ground truth" was not inferior to that of glass scoring, indicating that digital assessments can reliably replace traditional methods in clinical trial settings for liver disease.
View Article and Find Full Text PDF

Purpose: Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokines resulting in chronic inflammation, accelerated lipid peroxidation with further development of atherosclerotic alterations and diabetes. We have proposed a novel combinatorial approach using FDA approved compounds targeting IL-17a and DPP4 to ameliorate a significant portion of the clustered clinical risks in patients with metabolic syndrome.

View Article and Find Full Text PDF

Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. Traditional in vivo studies used to characterize clinical candidate's volume of distribution are error-prone, time- and cost-intensive and lack reproducibility in clinical settings. The paper demonstrates how a computational platform integrating machine learning optimization with mechanistic modeling can be used to simulate compound plasma concentration profile and predict tissue-plasma partition coefficients with high accuracy by varying the lipophilicity descriptor logP.

View Article and Find Full Text PDF

Fluoroquinolones (FQs) are a widespread class of broad-spectrum antibiotics prescribed as a first line of defense, and, in some cases, as the only treatment against bacterial infection. However, when administered orally, reduced absorption and bioavailability can occur due to chelation in the gastrointestinal tract (GIT) with multivalent metal cations acquired from diet, coadministered compounds (sucralfate, didanosine), or drug formulation. Predicting the extent to which this interaction reduces in vivo antibiotic absorption and systemic exposure remains desirable yet challenging.

View Article and Find Full Text PDF

The COVID-19 pandemic has reached over 100 million worldwide. Due to the multi-targeted nature of the virus, it is clear that drugs providing anti-COVID-19 effects need to be developed at an accelerated rate, and a combinatorial approach may stand to be more successful than a single drug therapy. Among several targets and pathways that are under investigation, the renin-angiotensin system (RAS) and specifically angiotensin-converting enzyme (ACE), and Ca-mediated SARS-CoV-2 cellular entry and replication are noteworthy.

View Article and Find Full Text PDF

The use of opioid analgesics in treating severe pain is frequently associated with putative adverse effects in humans. Topical agents that are shown to have high efficacy with a favorable safety profile in clinical settings are great alternatives for pain management of multimodal analgesia. However, the risk of side effects induced by transdermal absorption and systemic exposure is of great concern as they are challenging to predict.

View Article and Find Full Text PDF

Introduction: Transdermal drug delivery is gaining popularity as an alternative to traditional routes of administration. It can increase patient compliance because of its painless and noninvasive nature, aid compounds in bypassing presystemic metabolic effects, and reduce the likelihood of adverse effects through decreased systemic exposure. In silico physiological modeling is critical to predicting dermal exposure for a therapeutic and assessing the impact of different formulations on transdermal disposition.

View Article and Find Full Text PDF